STRO-003
ROR1-expressing solid tumors
PreclinicalActive (Partnered with Astellas)
Key Facts
Indication
ROR1-expressing solid tumors
Phase
Preclinical
Status
Active (Partnered with Astellas)
Company
About Sutro Biopharma
Sutro Biopharma is redefining cancer therapy through its innovative cell-free protein synthesis platform, XpressCF®, which allows for the rational design of optimized antibody-drug conjugates (ADCs). The company's core strategy involves developing single- and dual-payload ADCs aimed at overcoming treatment resistance and expanding the range of treatable tumors. With a public listing on NASDAQ and a leadership team rich in biotech experience, Sutro is advancing a clinical pipeline while leveraging its platform through strategic collaborations to create meaningful breakthroughs for patients.
View full company profile